GB0804755D0 - Therapeutic compounds - Google Patents

Therapeutic compounds

Info

Publication number
GB0804755D0
GB0804755D0 GBGB0804755.7A GB0804755A GB0804755D0 GB 0804755 D0 GB0804755 D0 GB 0804755D0 GB 0804755 A GB0804755 A GB 0804755A GB 0804755 D0 GB0804755 D0 GB 0804755D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic compounds
therapeutic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0804755.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority to GBGB0804755.7A priority Critical patent/GB0804755D0/en
Publication of GB0804755D0 publication Critical patent/GB0804755D0/en
Priority to JP2010550258A priority patent/JP2011513475A/ja
Priority to CA2716918A priority patent/CA2716918C/en
Priority to PCT/GB2009/000661 priority patent/WO2009112832A1/en
Priority to AU2009224004A priority patent/AU2009224004A1/en
Priority to US12/922,270 priority patent/US8362030B2/en
Priority to EP09719116A priority patent/EP2265611A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB0804755.7A 2008-03-14 2008-03-14 Therapeutic compounds Ceased GB0804755D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0804755.7A GB0804755D0 (en) 2008-03-14 2008-03-14 Therapeutic compounds
JP2010550258A JP2011513475A (ja) 2008-03-14 2009-03-13 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）の阻害剤としての三環式誘導体
CA2716918A CA2716918C (en) 2008-03-14 2009-03-13 Tricyclic derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
PCT/GB2009/000661 WO2009112832A1 (en) 2008-03-14 2009-03-13 Tricyclic derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
AU2009224004A AU2009224004A1 (en) 2008-03-14 2009-03-13 Tricyclic derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP)
US12/922,270 US8362030B2 (en) 2008-03-14 2009-03-13 Tricyclic derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP)
EP09719116A EP2265611A1 (en) 2008-03-14 2009-03-13 Tricyclic derivatives as inhibitors of poly(adp-ribose)polymerase (parp)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0804755.7A GB0804755D0 (en) 2008-03-14 2008-03-14 Therapeutic compounds

Publications (1)

Publication Number Publication Date
GB0804755D0 true GB0804755D0 (en) 2008-04-16

Family

ID=39328122

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0804755.7A Ceased GB0804755D0 (en) 2008-03-14 2008-03-14 Therapeutic compounds

Country Status (7)

Country Link
US (1) US8362030B2 (enExample)
EP (1) EP2265611A1 (enExample)
JP (1) JP2011513475A (enExample)
AU (1) AU2009224004A1 (enExample)
CA (1) CA2716918C (enExample)
GB (1) GB0804755D0 (enExample)
WO (1) WO2009112832A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216998B2 (en) 2012-02-15 2015-12-22 Janssen Pharmaceutica Nv Tricyclic indole derivatives useful endothelial lipase inhibitors
US9512486B2 (en) * 2012-08-06 2016-12-06 The Institute Of Cancer Research: Royal Cancer Hospital Materials, methods, and systems for treating cancer
KR101670126B1 (ko) 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
CN103936735B (zh) * 2014-04-04 2015-11-11 沈阳工业大学 氮杂苯并薁衍生物及其制备方法和用途
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
WO2018138050A1 (de) 2017-01-26 2018-08-02 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2019016110A1 (en) * 2017-07-18 2019-01-24 Lonza Ltd PROCESS FOR THE PREPARATION OF 5-FLUORO-2-METHYL-3-NITROBENZOIC ACID AND METHYL ESTER
US11001552B2 (en) 2017-07-18 2021-05-11 Lonza Ltd Method for preparation of 5-fluoro-2-methyl-3-nitrobenzoic acid and its methyl ester
SG11202108399PA (en) * 2019-02-02 2021-09-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Indolo heptamyl oxime analogue as parp inhibitor
WO2021214502A1 (en) 2020-04-21 2021-10-28 Idience Co., Ltd. Process for preparing a phthalazinone derivative and intermediates thereof
KR102913343B1 (ko) 2020-04-21 2026-01-15 아이디언스 주식회사 프탈라지논 화합물의 결정형
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
CN117105958B (zh) * 2022-05-24 2025-08-29 科岭源生物科技(深圳)有限公司 一种制备5-ht3受体调节剂的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
EP0771319A1 (en) 1994-07-15 1997-05-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
US5958942A (en) * 1994-07-15 1999-09-28 Takeda Chemical Industries, Ltd. Tricyclic nitrogen ring compounds, their production and use
CA2214393A1 (en) 1996-09-02 1998-03-02 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
AU5340298A (en) 1996-12-27 1998-07-31 Takeda Chemical Industries Ltd. Stabilized tricyclic compound
CA2332239A1 (en) * 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
EP1140936B1 (en) 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
KR20010087401A (ko) * 1999-09-28 2001-09-15 스타르크, 카르크 아제피노인돌 유도체, 그의 제법 및 용도
ES2290115T3 (es) 2000-02-01 2008-02-16 ABBOTT GMBH & CO. KG Compuestos heterociclicos y su aplicacion como inhibidores de parp.
FR2816942B1 (fr) 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
US6887996B2 (en) * 2000-12-01 2005-05-03 Guilford Pharmaceuticals Inc. Compounds and their use
JP2005514412A (ja) * 2001-12-27 2005-05-19 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 中枢神経系疾患を処置するために有用なアロイルピロールヘテロアリールおよびメタノール類
JP2006522088A (ja) 2003-03-31 2006-09-28 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤の塩
MXPA06000993A (es) * 2003-07-25 2006-08-31 Cancer Rec Tech Ltd Inhbidores triciclicos de parp.
CA2557547A1 (en) 2004-02-26 2005-09-09 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
KR20070057859A (ko) 2004-08-26 2007-06-07 쿠도스 파마슈티칼스 리미티드 4-헤테로아릴메틸 치환된 프탈라지논 유도체
US20090275619A1 (en) 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
JP5271897B2 (ja) * 2006-05-31 2013-08-21 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ ポリ（ＡＤＰ−リボース）ポリメラーゼ（ＰＡＲＰ）の阻害剤としての、ピロロ［１，２−ａ］ピラジン−１（２Ｈ）−オン及びピロロ［１，２−ｄ］［１，２，４］トリアジン−１（２Ｈ）−オン誘導体
GB0612971D0 (en) 2006-06-30 2006-08-09 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0615809D0 (en) 2006-08-09 2006-09-20 Istituto Di Ricerche D Biolog Therapeutic compounds

Also Published As

Publication number Publication date
CA2716918C (en) 2013-07-02
US20110053911A1 (en) 2011-03-03
EP2265611A1 (en) 2010-12-29
AU2009224004A1 (en) 2009-09-17
CA2716918A1 (en) 2009-09-17
JP2011513475A (ja) 2011-04-28
US8362030B2 (en) 2013-01-29
WO2009112832A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
GB0813740D0 (en) Therapeutic compounds
GB0811304D0 (en) Therapeutic agents
GB0806794D0 (en) Therapeutic compounds
GB0813087D0 (en) Therapeutic compounds
GB0716532D0 (en) Therapeutic compounds
GB0801081D0 (en) Therapeutic agents
GB0801080D0 (en) Therapeutic agents
GB0821693D0 (en) Therapeutic agents
GB0812309D0 (en) Therapeutic agents
GB0805818D0 (en) Therapeutic agents
GB0708188D0 (en) Therapeutic compounds
GB0702862D0 (en) Therapeutic compounds
EP2454276A4 (en) THERAPEUTIC AGENTS
GB0708186D0 (en) Therapeutic compounds
GB0906026D0 (en) Therapeutic compounds
GB0811715D0 (en) Therapeutic agents
GB0821817D0 (en) Therapeutic compounds
GB0811850D0 (en) Therapeutic compounds
GB0815700D0 (en) Therapeutic compounds
GB0816707D0 (en) Therapeutic compounds
GB0717573D0 (en) Therapeutic compounds
GB0717572D0 (en) Therapeutic compounds
GB0711886D0 (en) Therapeutic compounds
GB0713865D0 (en) Therapeutic compounds
GB0717571D0 (en) Therapeutic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)